12:23 PM EDT, 06/18/2024 (MT Newswires) -- Calliditas Therapeutics ( CALT ) recently received an approval of a patent from the US Patent and Trademark Office for the use of setanaxib in combination with a PD-1 inhibitor for cancer treatment, the company said Tuesday.

The patent will expire in 2039, it said.

The Swedish biopharmaceutical company has also applied for patents in Europe and elsewhere and has secured product protection in some territories.

Price: 38.83, Change: -0.41, Percent Change: -1.06